teprotide has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abiru, S; Aratake, K; Arima, K; Eguchi, K; Ida, H; Iwanaga, N; Izumi, Y; Kamachi, M; Kawakami, A; Migita, K; Mingguo, H; Miyashita, T; Nakashima, K; Nishikaku, F; Origuchi, T; Tagashira, S; Tamai, M; Tanaka, F | 1 |
1 other study(ies) available for teprotide and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arthritis, Rheumatoid; Cells, Cultured; Chromones; Enzyme Activation; Humans; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinases; Morpholines; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Synovial Membrane; Teprotide; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2003 |